Ricinoleic acid (purity≥85%)
Based on 1 Customer Validation
Ricinoleic acid (purity≥85%), a hydroxy fatty acid, is an attractive feedstock for the production of high-performance lubricants, cosmetics, polymers, surfactants, and coatings. Ricinoleic acid is the main active ingredient of Castor oil (HY-107799). Ricinoleic acid is the agonist for prostaglandin EP3 receptor (EP3 receptor) (EC50 in MEG-01 is 0.5 μM), that causes laxative effects and uterine contraction. Ricinoleic acid exhibits antianxiety-like, anti-inflammatory and pro-inflammatory properties.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 85.0%
- CAS. Nr.: 141-22-0
- Formel: C18H34O3
- Molecular Weight:298.46
-
Speicherung:
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Natural Product Library
HY-L021
-
Lipid Compound Library
HY-L043
-
Medicine Food Homology Compound Library
HY-L055
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Angiogenesis-Related Compound Library
HY-L088
-
Food-Sourced Compound Library
HY-L094
-
Inactive Ingredient Library
HY-L096
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Fatty Acids Compound Library
HY-L182
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Chinese Baijiu Compound Library
HY-L241
-
Natural Product Diversity Scaffold Library
HY-L245
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
Biologische Aktivität
Ricinoleic acid (10-100 μM, 24 h) inhibits the release of β-HEX in RBL-2H3 cells induced by DNP-BSA in a dose-dependent manner in RBL-2H3 cells[2].
Ricinoleic acid (10-100 μM, 24 h) inhibits glucose production in a dosedependent manner in H4IIE cells[2].
Ricinoleic acid (100 μM, 80 min) increases contractile activity in intestinal and uterine smooth muscle of wild-type mice, thereby promoting intestinal peristalsis and uterine contraction, leading to laxative effect and labor[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:H4IIE cells
-
Concentration:100 μM
-
Incubation Time:1 h
-
Result:Increased the level of GSK-3β phosphorylation at Ser9.
Increased the stability of β-catenin at the protein level.
Decreased the phosphorylated GS to total GS ratio.
Ricinoleic acid (0.3-100 mg/guinea pig, eyelid surface administration) enhances eyelid edema at low doses, suppresses eyelid edema after repeat application in Carrageenan (HY-125474)-induced guinea-pig eyelid edema models[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mouse elevated zero maze models[3]
-
Dosage:5%
-
Administration:single dose, sc
-
Result:Increased the open zone occupancy in the elevated zero maze.
-
Animal Model:Carrageenan-induced guinea-pig eyelid edema models[5]
-
Dosage:0.3-100 mg/guinea pig, or 0.9 mg/guinea pig for repeat application
-
Administration:eyelid surface administration, single dose or 8 days for repeat application
-
Result:Enhanced eyelid edema at low doses, suppressed eyelid edema after repeat application.
Chemical Information
-
CAS. Nr. 141-22-0
-
Appearance Liquid (Density: 0.940 g/cm3)
-
Molecular Weight 298.46
-
Formel C18H34O3
-
Color Light yellow to brown
-
SMILES
OC(CCCCCCC/C=C\C[C@H](O)CCCCCC)=O
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (335.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (8.38 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: Saline
Solubility: 1 mg/mL (3.35 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Tian B, et al. Identification of genes associated with ricinoleic acid accumulation in Hiptage benghalensis via transcriptome analysis. Biotechnol Biofuels. 2019 Jan 21;12:16. [Content Brief]
[2]. Yoshida J, et al. Inhibition of Calcineurin and Glycogen Synthase Kinase-3β by Ricinoleic Acid Derived from Castor Oil. Lipids. 2020 Mar;55(2):89-99. [Content Brief]
[3]. Nisbett KE, et al., Indulging Curiosity: Preliminary Evidence of an Anxiolytic-like Effect of Castor Oil and Ricinoleic Acid. Nutrients. 2024 May 18;16(10):1527. [Content Brief]
[4]. Tunaru S, et al., Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors. Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9179-84. [Content Brief]
[5]. Vieira C, et al., Pro- and anti-inflammatory actions of ricinoleic acid: similarities and differences with capsaicin. Naunyn Schmiedebergs Arch Pharmacol. 2001 Aug;364(2):87-95. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3505 mL | 16.7527 mL | 33.5053 mL | 83.7633 mL |
| 5 mM | 0.6701 mL | 3.3505 mL | 6.7011 mL | 16.7527 mL | |
| 10 mM | 0.3351 mL | 1.6753 mL | 3.3505 mL | 8.3763 mL | |
| 15 mM | 0.2234 mL | 1.1168 mL | 2.2337 mL | 5.5842 mL | |
| 20 mM | 0.1675 mL | 0.8376 mL | 1.6753 mL | 4.1882 mL | |
| 25 mM | 0.1340 mL | 0.6701 mL | 1.3402 mL | 3.3505 mL | |
| 30 mM | 0.1117 mL | 0.5584 mL | 1.1168 mL | 2.7921 mL | |
| 40 mM | 0.0838 mL | 0.4188 mL | 0.8376 mL | 2.0941 mL | |
| 50 mM | 0.0670 mL | 0.3351 mL | 0.6701 mL | 1.6753 mL | |
| 60 mM | 0.0558 mL | 0.2792 mL | 0.5584 mL | 1.3961 mL | |
| 80 mM | 0.0419 mL | 0.2094 mL | 0.4188 mL | 1.0470 mL | |
| 100 mM | 0.0335 mL | 0.1675 mL | 0.3351 mL | 0.8376 mL |
Ricinoleic acid (purity≥85%) Related Classifications
HY-N6070 Related Classifications
Powered by Bioz